We used two tumor xenograft mouse models to evaluate the in vivo anti‐tumor activity of CD3ε FP T cells: a tumor model based on the ovarian cancer OVCAR‐3 cell line, and a tumor model based on the rapidly growing B cell lymphoma Raji cell line. This evidence concerns the gene CD3E and B-cell non-Hodgkin lymphoma.